379 related articles for article (PubMed ID: 32079456)
1. MAFG-AS1 is a novel clinical biomarker for clinical progression and unfavorable prognosis in gastric cancer.
Li C; Wu R; Xing Y
Cell Cycle; 2020 Mar; 19(5):601-609. PubMed ID: 32079456
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis.
Li D; Zhong S; Zhu Z; Jiang X; Zhang J; Gu J; Chen F
Pathobiology; 2020; 87(6):345-355. PubMed ID: 33238264
[TBL] [Abstract][Full Text] [Related]
3. LncRNA MAFG-AS1 Upregulates Polo-Like Kinase-1 by Sponging miR-505 to Promote Gastric Adenocarcinoma Cell Proliferation.
Fu Y; Wen J; Li X; Gong M; Guo Z; Wang G
Crit Rev Eukaryot Gene Expr; 2021; 31(5):27-32. PubMed ID: 34591387
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MAFG-AS1 Promotes Lung Adenocarcinoma Cell Migration and Invasion by Targeting miR-3196 and Regulating SOX12 Expression.
Wu Q; Jiang J
Mol Biotechnol; 2022 Sep; 64(9):970-983. PubMed ID: 35275356
[TBL] [Abstract][Full Text] [Related]
5. LncRNA MAFG-AS1 is involved in human cancer progression.
Li P; Ma X; Gu X
Eur J Med Res; 2023 Nov; 28(1):497. PubMed ID: 37941063
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4.
Cui S; Yang X; Zhang L; Zhao Y; Yan W
Biochem Biophys Res Commun; 2018 Nov; 506(1):251-258. PubMed ID: 30348529
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MAFG-AS1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/MMP15.
Li H; Zhang GY; Pan CH; Zhang XY; Su XY
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2838-2846. PubMed ID: 31002134
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.
Jia YC; Wang JY; Liu YY; Li B; Guo H; Zang AM
Cell Biol Int; 2019 Apr; 43(4):384-393. PubMed ID: 30599080
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis.
Sui Y; Lin G; Zheng Y; Huang W
Eur J Pharmacol; 2019 Sep; 859():172465. PubMed ID: 31211984
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers.
Huang Z; Zhang M; Li J; Lou C
Biomed Pharmacother; 2023 Jul; 163():114756. PubMed ID: 37105079
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor ETV1-induced lncRNA MAFG-AS1 promotes migration, invasion, and epithelial-mesenchymal transition of pancreatic cancer cells by recruiting IGF2BP2 to stabilize ETV1 expression.
Weng H; Feng W; Li F; Huang D; Lin L; Wang Z
Growth Factors; 2023 Aug; 41(3):152-164. PubMed ID: 37428861
[TBL] [Abstract][Full Text] [Related]
13. HBx-upregulated MAFG-AS1 promotes cell proliferation and migration of hepatoma cells by enhancing MAFG expression and stabilizing nonmuscle myosin IIA.
Zhang F; Li Y; Gan L; Tong X; Qi D; Wang Q; Ye X
FASEB J; 2021 May; 35(5):e21529. PubMed ID: 33813778
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenic roles of MAFG-AS1 in human cancers.
Ahmadi M; Morshedzadeh F; Ghaderian SMH; Mousavi P; Habibipour L; Peymani M; Abbaszadegan MR; Ghafouri-Fard S
Clin Transl Oncol; 2024 Jan; 26(1):52-68. PubMed ID: 37351806
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1.
Bai Y; Ren C; Wang B; Xue J; Li F; Liu J; Yang L
Cancer Gene Ther; 2022 Mar; 29(3-4):277-291. PubMed ID: 34035482
[TBL] [Abstract][Full Text] [Related]
16. LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer.
Shi XY; Sun YZ; Li M; Li HY
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):232-238. PubMed ID: 31389606
[TBL] [Abstract][Full Text] [Related]
17. High-expression of LncRNA MAFG-AS1 is associated with the prognostic of patients with colorectal cancer.
Cui W; Wang Y; Shen X; Wu X; Liu H; Xu X
Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1530-1535. PubMed ID: 33295405
[TBL] [Abstract][Full Text] [Related]
18. Increased lncRNA AFAP1-AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer.
Feng Y; Zhang Q; Wang J; Liu P
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3842-3849. PubMed ID: 28975981
[TBL] [Abstract][Full Text] [Related]
19. LncRNA ASMTL-AS1/microRNA-1270 differentiate prognostic groups in gastric cancer and influence cell proliferation, migration and invasion.
Song Z; Wang J
Bioengineered; 2022 Jan; 13(1):1507-1517. PubMed ID: 34986743
[TBL] [Abstract][Full Text] [Related]
20. Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer.
Zhang W; Huang L; Lu X; Wang K; Ning X; Liu Z
Bosn J Basic Med Sci; 2019 May; 19(2):164-171. PubMed ID: 30821221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
